Vanda Up on EU News - Analyst Blog

An image of a compass on a chart
Credit: Shutterstock photo

Vanda Pharmaceuticals Inc. 's ( VNDA ) shares are up 25.3% on the news that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for Hetlioz (tasimelteon). The company is looking to get Hetlioz approved for the treatment of non-24-hour sleep-wake disorder (Non-24) in the totally blind.

Hetlioz is already approved in the U.S. for Non-24 where it was launched this April. It is the first approved drug in this indication. Hetlioz has orphan drug designation in the U.S. and the EU for this indication.

We remind investors that Vanda has a license agreement with Bristol-Myers Squibb ( BMY ) to develop and commercialize Hetlioz. Under this agreement, Vanda will pay up to $25 million once cumulative Hetlioz sales reach $250 million as well as royalties on net sales of Hetlioz.

According to the company, nearly 130,000 people in the EU suffer from Non-24 sleeping disorder. This disorder mostly affects people who are totally blind.

Meanwhile, Vanda is working on strengthening its pipeline. Under an agreement with Eli Lilly and Company ( LLY ), the company acquired an exclusive worldwide license to develop and commercialize VLY-686. Currently, VLY-686 is in a phase II study in patients suffering from chronic pruritus as a result of atopic dermatitis.

Additionally, Vanda has plans to initiate a pediatric study on Hetlioz for Non-24. We expect investor focus to remain on pipeline updates as well as Hetlioz's commercialization in the U.S.

Investors looking for well-positioned stocks in the biopharma sector may consider Gilead Sciences Inc. ( GILD ) carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

LILLY ELI & CO (LLY): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More